Novo Nordisk reports strong Phase 3 obesity drug data and EU haemophilia approval
Novo Nordisk announced that its experimental obesity drug CagriSema achieved average weight losses of about 20.7% and 21.0% in two lower‑dose regimens in a Phase 3 REDEFINE 9 trial, far exceeding the 2.0% loss seen with placebo. The company also received European Union marketing authorization for its haemophilia A therapy FREHEMGO and filed U.S. and EU applications for the sickle‑cell drug etavopivat. The news lifted the share price by roughly 2‑3% and came after the firm raised its full‑year 2026 adjusted revenue and profit growth outlook to a range of –2% to +2% at constant exchange rates.
Why it matters
The trial results suggest CagriSema could become a major revenue driver in the growing obesity market, which may boost future sales and earnings. The EU approval of FREHEMGO adds a new product to Novo Nordisk’s haemophilia portfolio, expanding its revenue base. The raised guidance signals management confidence despite modest growth expectations.
Key facts
- 1Novo Nordisk stock rose 2.7% to DKK 286.1. investing.com
- 2CagriSema lower‑dose regimens (1.7 mg/1.7 mg and 1.0 mg/1.0 mg) produced estimated average weight loss of 20.7% and 21.0% at week 68. investing.com
- 3Placebo participants lost 2.0% of body weight at week 68. investing.com
- 467.8% of CagriSema recipients lost at least 5% of weight within eight weeks; early responders averaged 25.4% loss at week 68 versus 17.8% for slower responders. investing.com
- 5EU marketing authorization was granted for FREHEMGO (denecimig). investing.com
- 6Regulatory applications were submitted for etavopivat in the United States and Europe. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.